- $137.05m
- -$42.83m
Brief: Commander Aggregator Lp Reports 6.17% Stake In Compass Therapeutics Inc As Of Nov 4
U.S. RESEARCH ROUNDUP-Amyris, HanesBrands, Roblox
Brief: Compass Therapeutics Reports Q3 Financial Results, Provides Corporate Update
Brief: Compass Therapeutics Announces $80 Million Private Placement
Brief: Compass Therapeutics Announces Clinical Collaboration With Merck To Evaluate Ctx-471 In Combination With Keytruda® (Pembrolizumab)
Brief: Compass Therapeutics Reports Second Quarter 2022 Financial Results And Provides Corporate Update
Brief: Entera Bio Announces Execution Of Key Regulatory Milestones For Eb613, The First Oral Anabolic Drug Proposed For The Treatment Of Osteoporosis Miranda Toledano Assumes CEO Position
U.S. STOCKS ON THE MOVE-JPMorgan, Citigroup, Broadcom, VMware
U.S. STOCKS ON THE MOVE-JPMorgan, Etsy, Ross Stores, VMware
Compass Therapeutics rises as Wainwright cheers co's lead asset, cash position
Brief: Entera Bio Board Member, Miranda Toledano, To Assume Role Of Chief Business Officer, Chief Financial Officer, And Head Of Corporate Strategy
Brief: Compass Therapeutics Reports First Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP- Bioatla, BRF, Tegna
Brief: Compass Therapeutics Reports Positive Interim Phase 2 Data Of Ctx-009
Brief: Compass Therapeutics Announces Presentation On CTX-8371, A Bispecific Antibody Targeting Pd-1 And Pd-L1, At The 2022 AACR Annual Meeting In New Orleans
Brief: Compass Therapeutics Reports Q4 Loss Per Share Of $0.15
Brief: Compass Therapeutics Announces Us FDA Clearance Of Application For A Phase 2 Study Of Ctx-009, A Bispecific Antibody
Brief: Compass Therapeutics, Inc. Files Prospectus Related To Offering
Brief: Compass Therapeutics Reports Q3 Loss Per Share $0.10